Unicycive Therapeutics Stock (NASDAQ:UNCY)
Previous Close
$1.03
52W Range
$0.47 - $1.82
50D Avg
$1.26
200D Avg
$0.94
Market Cap
$39.11M
Avg Vol (3M)
$401.78K
Beta
2.71
Div Yield
-
UNCY Company Profile
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.